Topics in Practice ManagementT argeted temperature management (TTM) has been intermittently used for over 100 years but has only recently achieved a mainstream role in clinical practice. In the early 1900s, Russian clinicians placed snow on patients in cardiac arrest in an attempt to achieve return of spontaneous circulation (ROSC). 1 In 1937, Fay 2 applied refrigeration to patients with cancer and observed tumor shrinkage and devascularization. In 1958, Williams and Spencer 3 published a case series of patients resuscitated from intraoperative arrest, demonstrating better neurologic outcomes when patients received TTM. The guideline for heart-lung resuscitation by Safar, 4 published in 1964, recommended the initiation of hypothermia if there was no sign of neurologic recovery within 30 min of arrest. These early implementation attempts did not translate into widespread clinical use, and it was not until 2002 that major clinical trials were published readdressing the effi cacy of TTM in postarrest patients. 5,6 Current clinical indications for TTM as a neuroprotective therapy include adult patients with postcardiac arrest syndrome (PCAS) and neonates with hypoxicischemic encephalopathy (HIE); success in these conditions, coupled with lessons learned from early failures in the implementation of TTM, has motivated investigators to reconsider this therapy for other disease processes, including ischemic stroke, traumatic brain injury (TBI), hepatic encephalopathy, septic shock, and acute myocardial infarction. These entities will be further examined in this review of clinical TTM use.